Yesterday, the EveryLife Foundation’s Chief of Policy and Advocacy, Annie Kennedy, testified at the U.S. FDA Public Meeting on the Reauthorization of the Prescription Drug User Fee Act (PDUFA) Reauthorization. Annie spoke both in her role with the Foundation, and as a member of The PFDDworks Collaborative.
PFDDworks Collaborative members include the National Psoriasis Foundation, the Amyloidosis Research Consortium, the LUNGevity Foundation, the Michael J. Fox Foundation for Parkinson’s Research, the COPD Foundation, the Lupus Foundation of America, the ALS Association, the National Eczema Association, the Medical Research Fund, Parent Project Muscular Dystrophy, and the EveryLife Foundation for Rare Diseases.
PFDD stands for patient focused drug development and has been at the heart of the Foundation’s mission since its founding.
During her testimony, Annie focused on four priorities areas for further expansion: transparency, authenticity, consistency, and comprehensiveness. Read Annie’s complete testimony
Learn about the Prescription Drug User Fee Act and its impact on the rare disease community by watching the Rare Disease Legislative Advocate’s July 2020 monthly webinar.
